Cargando…

Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review

Streptococcus agalactiae, a Gram-positive bacterium, causes invasive infection known as Group B streptococcal disease (GBS). It is a leading cause of neonatal death and complications prior to delivery. The burden of GBS is unknown in India despite the high incidence of preterm and stillbirths. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghia, Canna, Rambhad, Gautam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445532/
https://www.ncbi.nlm.nih.gov/pubmed/34540226
http://dx.doi.org/10.1177/20499361211045253
_version_ 1784568679083540480
author Ghia, Canna
Rambhad, Gautam
author_facet Ghia, Canna
Rambhad, Gautam
author_sort Ghia, Canna
collection PubMed
description Streptococcus agalactiae, a Gram-positive bacterium, causes invasive infection known as Group B streptococcal disease (GBS). It is a leading cause of neonatal death and complications prior to delivery. The burden of GBS is unknown in India despite the high incidence of preterm and stillbirths. In this study, we performed a narrative review of the available literature (published in the last 10 years) on the epidemiology of GBS, using PubMed and Google Scholar, to understand its impact in India and evaluate potential strategies to prevent the disease in the high-risk population, that is, neonates. The review showed that the incidence of early- and late-onset GBS in neonates (per 1000 live births) was in the ranges of 0.090–0.68 and 0.0–0.07 respectively. The overall case fatality rate reported in only one study was 0.63. In pregnant women, the prevalence of GBS colonization was 2–62% and its transmission to their newborns varied from 6.7% to 11.1%. The serotype distribution of GBS is unclear, but some studies reported the distribution of types Ia, Ib, II, III, V, VII among pregnant women in India. The associated risk factors for GBS colonization in pregnant women are unclear but a few studies suggest the role of age and multigravida, while the risk factors in neonates include preterm birth, prolonged rupture of membrane (⩾18 h), maternal fever, obstetric complications, and prolonged labor >18 h. Screening of GBS is not a routine practice in India and intrapartum antibiotics prophylaxis is limited to only in risk conditions to prevent neonatal disease transmission. A few studies also suggest that high birth rate, poor detection methods, and financial constraints limit routine GBS screening in a developing country such as India. Hence, maternal vaccination is the most promising strategy to prevent neonatal GBS and Pfizer’s hexavalent GBS conjugate vaccine (GBS6) is being developed for GBS neonatal disease.
format Online
Article
Text
id pubmed-8445532
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84455322021-09-17 Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review Ghia, Canna Rambhad, Gautam Ther Adv Infect Dis Review Streptococcus agalactiae, a Gram-positive bacterium, causes invasive infection known as Group B streptococcal disease (GBS). It is a leading cause of neonatal death and complications prior to delivery. The burden of GBS is unknown in India despite the high incidence of preterm and stillbirths. In this study, we performed a narrative review of the available literature (published in the last 10 years) on the epidemiology of GBS, using PubMed and Google Scholar, to understand its impact in India and evaluate potential strategies to prevent the disease in the high-risk population, that is, neonates. The review showed that the incidence of early- and late-onset GBS in neonates (per 1000 live births) was in the ranges of 0.090–0.68 and 0.0–0.07 respectively. The overall case fatality rate reported in only one study was 0.63. In pregnant women, the prevalence of GBS colonization was 2–62% and its transmission to their newborns varied from 6.7% to 11.1%. The serotype distribution of GBS is unclear, but some studies reported the distribution of types Ia, Ib, II, III, V, VII among pregnant women in India. The associated risk factors for GBS colonization in pregnant women are unclear but a few studies suggest the role of age and multigravida, while the risk factors in neonates include preterm birth, prolonged rupture of membrane (⩾18 h), maternal fever, obstetric complications, and prolonged labor >18 h. Screening of GBS is not a routine practice in India and intrapartum antibiotics prophylaxis is limited to only in risk conditions to prevent neonatal disease transmission. A few studies also suggest that high birth rate, poor detection methods, and financial constraints limit routine GBS screening in a developing country such as India. Hence, maternal vaccination is the most promising strategy to prevent neonatal GBS and Pfizer’s hexavalent GBS conjugate vaccine (GBS6) is being developed for GBS neonatal disease. SAGE Publications 2021-09-14 /pmc/articles/PMC8445532/ /pubmed/34540226 http://dx.doi.org/10.1177/20499361211045253 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Ghia, Canna
Rambhad, Gautam
Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review
title Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review
title_full Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review
title_fullStr Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review
title_full_unstemmed Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review
title_short Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review
title_sort disease burden due to group b streptococcus in the indian population and the need for a vaccine – a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445532/
https://www.ncbi.nlm.nih.gov/pubmed/34540226
http://dx.doi.org/10.1177/20499361211045253
work_keys_str_mv AT ghiacanna diseaseburdenduetogroupbstreptococcusintheindianpopulationandtheneedforavaccineanarrativereview
AT rambhadgautam diseaseburdenduetogroupbstreptococcusintheindianpopulationandtheneedforavaccineanarrativereview